Active Not Recruiting PHASE2 INTERVENTIONAL 3-arm NCT06018467

Senolytics to Improve Osteoporosis Therapy (SENIOR)

SENolytics to Improve Osteoporosis Therapy: a Randomised Controlled Clinical Trial The SENIOR Trial

Sponsor: Odense Patient Data Explorative Network

Conditions Age-related Bone Loss Osteopenia, Osteoporosis

Interventions Dasatinib 100 Mg Oral Tablet Nicotinamide Riboside 1g (oral) Quercetin 1.250 mg (oral)

Updated 6 times since 2023 Last updated: Jan 26, 2026 Started: Sep 6, 2023 Primary completion: Apr 30, 2026 Completion: Apr 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06018467, this PHASE2 trial focuses on Age-related Bone Loss and Osteopenia, Osteoporosis and remains ongoing. Sponsored by Odense Patient Data Explorative Network, it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Aug 2025 — Feb 2026 [monthly]

Recruiting PHASE2
Sep 2024 — Aug 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Jul 2024 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Sep 2023 — Nov 2023 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Odense Patient Data Explorative Network
Odense University Hospital
The Novo Nordisk Foundation Center for Basic Metabolic Research

Data source: Odense University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Odense, Denmark